By Isabel Demetz (Reuters) -Swiss contract drugmaker Lonza plans to simplify its structure and exit its capsules and health ...

The life-sciences company will focus on its core business, including drug development, with restructuring and a divestment ...

Swiss contract drugmaker Lonza plans to exit its capsules and health ingredients (CHI) business, it said on Thursday, after ...

With a new CEO at the helm, Swiss CDMO Lonza is looking to revivify its business by doubling down on contract manufacturing ...

Swiss healthcare manufacturing organization Lonza saw its shares rise 7% to 559.40 francs in early trading, as it announced ...

Lonza Group AG / Key word (s): Strategic Company Decision Lonza Investor Update 2024 Outlines Strategy, New Organizational Structure and Guidance 12-Dec-2024 / 06:25 CET/CEST Release of an ad hoc ...

Investing.com -- Lonza’s shares rose over 6% on Thursday following the company’s announcement of plans to divest its Capsules ...

Elevation Oncology has tapped Lonza’s Synaffix to support the expansion of its pipeline, agreeing to pay up to $368 million ...

Lonza Group Ltd (GB:0QNO) has released an update.Pick the best stocks and maximize your portfolio:Discover top-rated stocks from highly ranked ...

Synaffix B.V., a Lonza company (SIX: LONN) focused on commercializing its clinical-stage platform technology for the development ...

A $1 million fence designed to protect one of the world’s most important wildlife populations is once again falling down.

Recent developments in the health sector include a dosing pause in Keros Therapeutics' drug trial, Corcept Therapeutics' ALS ...